SRRK

Over the past six months, SRRK's stock price has been impacted by several key events. The FDA issued a Complete Response Letter (CRL) for apitegromab in September 2025, which was followed by a resubmission of the Biologics License Application (BLA) in March 2026 after a Type A meeting with the FDA. Scholar Rock reported a positive Q4 2025 earnings beat and a positive Q1 2026 outlook, but also reported a larger net loss in Q1 2026. Analysts have shown strong confidence in the company, with several financial institutions raising their price targets. Scholar Rock strengthened its balance sheet by raising $111.8 million and drawing $200 million under a new term loan facility. Insiders have sold $5.0 million worth of shares, while an independent director exercised options to buy approximately $4.2 million worth of stock.